HC Wainwright reissued their buy rating on shares of Shattuck Labs (NASDAQ:STTK - Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $28.00 price objective on the stock.
Separately, Needham & Company LLC reissued a buy rating and set a $12.00 target price on shares of Shattuck Labs in a research note on Tuesday, April 9th.
Read Our Latest Stock Report on STTK
Shattuck Labs Stock Performance
Shares of NASDAQ STTK traded up $0.24 during midday trading on Thursday, hitting $11.10. The company's stock had a trading volume of 250,934 shares, compared to its average volume of 358,392. Shattuck Labs has a 1-year low of $1.33 and a 1-year high of $11.58. The firm's fifty day moving average price is $9.34 and its 200-day moving average price is $6.85. The firm has a market cap of $527.81 million, a P/E ratio of -5.41 and a beta of 1.98.
Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.10. The firm had revenue of $0.71 million during the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%. As a group, research analysts predict that Shattuck Labs will post -1.85 earnings per share for the current fiscal year.
Insider Transactions at Shattuck Labs
In other news, insider Stephen Stout sold 16,004 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the sale, the insider now directly owns 74,437 shares of the company's stock, valued at approximately $783,821.61. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.89% of the company's stock.
Institutional Trading of Shattuck Labs
Institutional investors have recently made changes to their positions in the stock. Cannon Global Investment Management LLC bought a new stake in shares of Shattuck Labs in the 1st quarter worth approximately $91,000. Tower Research Capital LLC TRC raised its holdings in shares of Shattuck Labs by 79.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company's stock worth $97,000 after purchasing an additional 5,989 shares in the last quarter. Reliant Investment Management LLC bought a new stake in shares of Shattuck Labs in the 4th quarter worth approximately $143,000. SG Americas Securities LLC bought a new stake in shares of Shattuck Labs in the 4th quarter worth approximately $268,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Shattuck Labs in the 4th quarter worth approximately $713,000. 58.74% of the stock is owned by institutional investors and hedge funds.
About Shattuck Labs
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
See Also
Before you consider Shattuck Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.
While Shattuck Labs currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
